PL2046394T3 - Zastosowanie sekwencji kwasów nukleinowych do leczenia chorób neurologicznych i psychiatrycznych, wektory i kompozycje - Google Patents

Zastosowanie sekwencji kwasów nukleinowych do leczenia chorób neurologicznych i psychiatrycznych, wektory i kompozycje

Info

Publication number
PL2046394T3
PL2046394T3 PL07769040T PL07769040T PL2046394T3 PL 2046394 T3 PL2046394 T3 PL 2046394T3 PL 07769040 T PL07769040 T PL 07769040T PL 07769040 T PL07769040 T PL 07769040T PL 2046394 T3 PL2046394 T3 PL 2046394T3
Authority
PL
Poland
Prior art keywords
neurological
vectors
compositions
treatment
nucleic acid
Prior art date
Application number
PL07769040T
Other languages
English (en)
Inventor
Merab Kokaia
David Woldby
Original Assignee
Combigene Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combigene Ab filed Critical Combigene Ab
Publication of PL2046394T3 publication Critical patent/PL2046394T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL07769040T 2006-07-04 2007-07-04 Zastosowanie sekwencji kwasów nukleinowych do leczenia chorób neurologicznych i psychiatrycznych, wektory i kompozycje PL2046394T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0601456 2006-07-04
PCT/SE2007/050494 WO2008004972A2 (en) 2006-07-04 2007-07-04 Use of nucleic acid sequences for the treatment of neurological and psychiatric diseases, vectors and compositions
EP07769040.2A EP2046394B1 (en) 2006-07-04 2007-07-04 Use of nucleic acid sequences for the treatment of neurological and psychiatric diseases, vectors and compositions

Publications (1)

Publication Number Publication Date
PL2046394T3 true PL2046394T3 (pl) 2015-05-29

Family

ID=38895036

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07769040T PL2046394T3 (pl) 2006-07-04 2007-07-04 Zastosowanie sekwencji kwasów nukleinowych do leczenia chorób neurologicznych i psychiatrycznych, wektory i kompozycje

Country Status (5)

Country Link
US (1) US8901094B2 (pl)
EP (1) EP2046394B1 (pl)
ES (1) ES2532848T3 (pl)
PL (1) PL2046394T3 (pl)
WO (1) WO2008004972A2 (pl)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2749479C1 (ru) * 2016-02-12 2021-06-11 Комбиджен Аб Вектор

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103173454B (zh) * 2011-12-23 2015-07-01 青岛大学 一种强迫性障碍相关基因GalR1的多态性位点及其应用
WO2013119800A1 (en) 2012-02-07 2013-08-15 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
US9724396B2 (en) 2013-03-15 2017-08-08 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
CN103290007A (zh) * 2013-06-27 2013-09-11 华东理工大学 神经肽Y的cRNA原位杂交探针及其制备方法
US10317418B2 (en) 2015-02-24 2019-06-11 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
AU2001271838A1 (en) * 2000-07-06 2002-01-21 Bayer Corporation Human neuropeptide y-like g protein-coupled receptor
AU2003223766A1 (en) * 2002-04-30 2003-11-17 University Of North Carolina At Chapel Hill Secretion signal vectors
EP1680145A4 (en) 2003-10-14 2007-05-23 Neurologix Res Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASES

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2749479C1 (ru) * 2016-02-12 2021-06-11 Комбиджен Аб Вектор

Also Published As

Publication number Publication date
US20100010070A1 (en) 2010-01-14
EP2046394A2 (en) 2009-04-15
WO2008004972A2 (en) 2008-01-10
WO2008004972A3 (en) 2008-03-06
US8901094B2 (en) 2014-12-02
EP2046394A4 (en) 2010-08-11
ES2532848T3 (es) 2015-04-01
EP2046394B1 (en) 2014-12-17

Similar Documents

Publication Publication Date Title
IL187168A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
ZA200707591B (en) Dihyrothienopyrimidines for the treatment of inflammatory diseases
GB201001047D0 (en) Methods and compositions for the treatment of neurological disorders
GB0715745D0 (en) Liquid formulations for treatment of diseases or conditions
PT1613296E (pt) Métodos para o tratamento da doença de parkinson
IL190779A0 (en) Compositions for treatment of eye diseases
WO2007097981A3 (en) Alpha carbolines and uses thereof
IL206277A0 (en) 1,2,4-oxadiazole compounds for the treatment of autoimmune diseases
EP2187898B8 (en) Use of viral vectors carrying the cyp46a1 gene for the treatment of alzheimer's disease
WO2004093807A3 (en) Somatostatin vectors
PL2046394T3 (pl) Zastosowanie sekwencji kwasów nukleinowych do leczenia chorób neurologicznych i psychiatrycznych, wektory i kompozycje
EG24051A (en) Process for the purification of olefinically unsaturated nitriles
GB0909297D0 (en) Composition for the treatment of skin conditions
PL1982178T3 (pl) Sposoby leczenia zaburzeń afektywnych
GB0523961D0 (en) The treatment of ophthalmic diseases
EP1740221A4 (en) METHOD AND COMPOSITIONS FOR TREATING POLYCYSTIC DISEASES
PL2307380T3 (pl) Pochodne N’-nitroksyalkilonikotynamidu do leczenia chorób układu sercowo-naczyniowego
EP1781318A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF POLYKYSTIC DISEASES
WO2009140649A3 (en) Rab3b for the treatment and prevention of parkinson's disease
EP1865952A4 (en) COMPOSITIONS CONTAINING HISTAMINES FOR THE TREATMENT OF ALLERGIES
EP1996721A4 (en) NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES AND METHODS OF USING THEM IN DIAGNOSIS
GB0501129D0 (en) Method of treatment by administration of RNA
ZA200606780B (en) Compounds for the treatment of diseases
ZA200610483B (en) Process for the preparation of nateglinide
GB0501128D0 (en) Method of treatment by administration of RNA